相关实验视频
Updated: May 31, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.3K
在阿尔茨海默氏病中,与粉样蛋白相关的超连接性驱动tau在连接的大脑区域中传播
Sebastian N Roemer-Cassiano1,2,3, Fabian Wagner2, Lisa Evangelista2
1Department of Neurology, University Hospital, LMU Munich, 81377 Munich, Germany.
Science translational medicine
|January 22, 2025
概括
胺β (Aβ) 通过增加神经元超连接性,促进阿尔茨海默病中的传播. 这项研究揭示了叶中Aβ诱导的超连接性驱动了在脆弱的大脑区域的积,这表明了新的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 医疗成像医学成像
背景情况:
- 阿尔茨海默病 (AD) 涉及粉样β (Aβ) 和病理,但这种联系尚不清楚.
- 已知Aβ会导致神经元过度活跃,而tau则通过活跃的神经元网络传播.
- 了解Aβ如何影响tau的传播对于开发有效的AD疗法至关重要.
研究的目的:
- 调查神经元过度活跃和超连接性是否介于阿尔茨海默病中Aβ驱动的病理传播.
- 探索Aβ,神经元连接和tau积累之间的因果关系.
主要方法:
- 结合的Aβ-PET,静止状态fMRI和纵向的tau-PET在整个AD频谱中的个人中.
- 利用调解分析来评估Aβ,连接性和tau积累之间的关系.
- 在一个独立的队列中重复发现,以确认事件的时间序列.
主要成果:
- 发现Aβ诱导叶tau中心和对tau易受伤害的大脑后部区域之间的超连接.
- 观察到这种由Aβ诱导的超连接性在新皮质扩散之前发生.
- 增加的连接性显著介导了Aβ对加速tau积累的影响,建立了潜在的因果关系.
结论:
- 神经元过度连接是Aβ促进阿尔茨海默病中tau病理传播的关键机制.
- 针对Aβ诱导的神经元超连接性可能提供一种新的治疗策略,以减缓阿尔茨海默病中tau的传播和神经退行.
相关概念视频
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439
Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160

